BioStem Technologies Q2 Earnings Call Highlights

BioStem Technologies Q2 Earnings Call Highlights

Second-quarter revenue rose to $7.9 million from $6.1 million in the first quarter, driven by hospital revenue growth to $6.7 million and increased physician-office sales.

BioStem raised the low end of its 2026 revenue outlook to $26 million-$29 million.

BioStem is shifting toward a hospital-focused model, expanding its sales force, GPO access and adoption of its Neox, Clarix and VENDAJE products.

The company also completed its Nasdaq uplisting, which management expects to improve visibility and capital-market access.

The company reported a $9 million GAAP net loss and ended the quarter with $7 million in cash after $5.5 million of operating cash use. Management plans to move Neox and Clarix manufacturing in-house in the first half of 2027, potentially adding 15-20 percentage points to gross margins, while evaluating financing options for a $10 million contingent payment.

BioStem Technologies OTCMKTS: BSEM reported second-quarter revenue of $7.9 million as the company continued its transition to a predominantly hospital-focused commercial model. Revenue increased from $6.1 million in the first quarter, supported by higher hospital sales, expanded commercial coverage and a full quarter of contribution from its acquired business.

Hospital revenue rose sequentially to $6.7 million from $5.4 million in the first quarter, while physician office revenue increased to $1.1 million from $772,000.

Chief Executive Officer Jason Matuszewski said the second quarter was the company’s first full quarter operating primarily as a hospital-focused business.

“During the quarter, we increased hospital revenue sequentially to $6.7 million, completed the implementation of BioStem's own customer relationship management system, and continued building the commercial organization needed to support our growth strategy,” Matuszewski said.

After the quarter ended, BioStem completed its uplisting to the Nasdaq Capital Market, with its common stock beginning trading on Nasdaq on Aug. 7. Matuszewski said the listing expands the company’s visibility and access to capital markets while supporting talent recruitment and retention.

Commercial Expansion and Hospital Strategy BioStem is concentrating its commercial resources on hospital adoption of its Neox, Clarix and VENDAJE product lines. Chief Commercial Officer Barry Hassett said the products serve surgical and wound-care applications including urology, orthopedics, spine, women’s health, foot and ankle, colorectal surgery, and acute and chronic wound care. The company estimates these applications represent a $26 billion addressable market.

The company is seeking to add surgeons and hospital accounts while increasing utilization among existing users. Hassett said BioStem remains on track to have more than 40 W-2 sales representatives and more than 30 independent sales agents by year-end. At the time of the call, the company had 30 direct representatives and five regional directors.

BioStem has group purchasing organization agreements that provide access to member facilities representing more than 70% of U.S. hospital beds, according to Hassett. The company is working to add the VENDAJE line to applicable GPO contracts.

The company also introduced its BioRetain dry products to the hospital sales organization during the quarter. It completed the first phase of a customer relationship management platform integrated with its enterprise resource planning system, bringing sales logistics, operational support, invoicing and collections in-house after operating under a transition services agreement with BioTissue. Hassett said the company received eight U.S. design patents during the quarter related to fenes...